INDUCTION OF SECOND TRIMESTER ABORTION BY INTRAAMNIOTIC ADMINISTRATION OF 15(S)15 METHYL PGF_2α

Area of Science:

• Reproductive Medicine
• Pharmacology

Background:

• Second-trimester pregnancy termination is a critical aspect of reproductive healthcare.
• Prostaglandins are widely used for medical induction of abortion.
• 15(S)15 methyl PGF2α is a synthetic prostaglandin analog with potential therapeutic applications.

Purpose of the Study:

• To evaluate the efficacy and safety of intra-amniotic 15(S)15 methyl PGF2α for second-trimester pregnancy termination.
• To compare the induction-abortion interval and side effect profiles between primigravida and multigravida women.

Main Methods:

• A multicenter trial involving 139 women at 15-20 weeks gestation.
• Administration of 2.5 mg 15(S)15 methyl PGF2α via intra-amniotic route.
• Monitoring of abortion rates, induction-abortion interval, and adverse events.

Main Results:

• High abortion rates: 97% in primigravida and 94.5% in multigravida.
• Mean induction-abortion intervals: 22.8 hours (primigravida) and 18.3 hours (multigravida).
• Low incidence of gastrointestinal side effects (vomiting, diarrhea) and no genital tract injuries reported.

Conclusions:

• Intra-amniotic 15(S)15 methyl PGF2α is an effective and safe method for second-trimester pregnancy termination.
• The treatment demonstrates favorable efficacy in both primigravida and multigravida populations.
• Minimal side effects and absence of genital tract trauma contribute to its therapeutic profile.